Capricor Therapeutics (CAPR) Change in Accured Expenses (2010 - 2026)

Capricor Therapeutics' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at -$3.1 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 334.27% year-over-year to -$3.1 million; the TTM figure through Mar 2026 stood at $1.6 million (down 51.28% YoY), while the FY2025 annual figure was $6.0 million, up 208.27% from the prior year.
• Change in Accured Expenses was -$3.1 million for Q1 2026 at Capricor Therapeutics, down from $2.2 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $2.2 million in Q4 2022 to a low of -$3.1 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged $464028.2 across 5 years, with a median of $407203.0 in 2022.
• The sharpest annual moves came in 2022 and 2025: Change in Accured Expenses tumbled 828.57% in 2022, then soared 83134.6% in 2025.
• A 5-year view of Change in Accured Expenses shows it stood at $2.2 million in 2022, then plunged by 124.25% to -$541709.0 in 2023, then soared by 406.44% to $1.7 million in 2024, then soared by 30.61% to $2.2 million in 2025, then slumped by 242.11% to -$3.1 million in 2026.
• The last three Change in Accured Expenses figures came in at -$3.1 million (Q1 2026), $2.2 million (Q4 2025), and $971647.0 (Q3 2025), per Business Quant data.